Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 299

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

β-Adrenergic Receptor Polymorphisms and Response to Salmeterol

Open access
Wechsler, Michael E., Lehman, Erik, Lazarus, Stephen C., Lemanske, Robert F., Boushey, Homer A., Deykin, Aaron, Fahy, John V., Sorkness, Christine A., Chinchilli, Vernon M., Craig, Timothy J., DiMango, Emily, Kraft, Monica, Leone, Frank, Martin, Richard J., Peters, Stephen P., Szefler, Stanley J., Liu, Wenlei, Israel, Elliot·2006·American Journal of Respiratory and Critical Care Medicine

Abstract

RATIONALE: Several studies suggest that patients with asthma who are homozygous for arginine at the 16th position of the beta2-adrenergic receptor may not benefit from short-acting beta-agonists. OBJECTIVES: We investigated whether such genotype-specific effects occur when patients are treated with long-acting beta-agonists and whether such effects are modified by concurrent inhaled corticosteroid (ICS) use. METHODS: We compared salmeterol response in patients with asthma homozygous for arginine at B16 (B16Arg/Arg) with those homozygous for glycine at B16 (B16Gly/Gly) in two separate cohorts. In the first, subjects were randomized to regular therapy with salmeterol while simultaneously discontinuing ICS therapy. In the second, subjects were randomized to regular therapy with salmeterol while continuing concomitant ICS. RESULTS: In both trials, B16Arg/Arg subjects did not benefit compared with B16Gly/Gly subjects after salmeterol was initiated. In the first cohort, compared with placebo, the addition of salmeterol was associated with a 51.4 L/min lower A.M. peak expiratory flow (PEF; p = 0.005) in B16Arg/Arg subjects(salmeterol, n = 12; placebo, n = 5) as compared with B16Gly/Gly subjects (salmeterol, n = 13; placebo, n = 13). In the second cohort, B16Arg/Arg subjects treated with salmeterol and ICS concurrently (n = 8) had a lower A.M. PEF (36.8 L/min difference, p = 0.048) than B16Gly/Gly subjects (n = 22) treated with the same regimen. In addition, B16 Arg/Arg subjects in the second cohort had lower FEV1 (0.42 L, p = 0.003), increased symptom scores (0.2 units, p = 0.034), and increased albuterol rescue use (0.95 puffs/d, p = 0.004) compared with B16Gly/Gly subjects. CONCLUSIONS: Relative to B16Gly/Gly patients with asthma, B16Arg/Arg patients with asthma may have an impaired therapeutic response to salmeterol in either the absence or presence of concurrent ICS use. Investigation of alternate treatment strategies may benefit this group.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1164/rccm.200509-1519oc

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

See all 299

Metadata

Authors
Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F., Boushey, H. A., Deykin, A., Fahy, J. V., Sorkness, C. A., Chinchilli, V. M., Craig, T. J., DiMango, E., Kraft, M., Leone, F., Martin, R. J., Peters, S. P., Szefler, S. J., Liu, W., & Israel, E.
Venue
American Journal of Respiratory and Critical Care Medicine
Published
2006-03-01
Volume
173
Issue
5
Pages
519-526
ISSN
  • 1073-449X (ISSN-L)
  • 1535-4970
OpenAlex
W2113096218
Cited by
299
References
2
FWCI
21.53
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: β-Adrenergic Receptor Polymorphisms and Response to Salmeterol. https://app.cochat.ai/papers/10.1164/rccm.200509-1519oc
The paper
Wechsler, M. E., Lehman, E., Lazarus, S. C., Lemanske, R. F., Boushey, H. A., Deykin, A., Fahy, J. V., Sorkness, C. A., Chinchilli, V. M., Craig, T. J., DiMango, E., Kraft, M., Leone, F., Martin, R. J., Peters, S. P., Szefler, S. J., Liu, W., & Israel, E. (2006). β-Adrenergic Receptor Polymorphisms and Response to Salmeterol. American Journal of Respiratory and Critical Care Medicine. https://doi.org/10.1164/rccm.200509-1519oc

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.